

## Outcome of Targeted vs Empiric Antibiotic Therapy in the Treatment of Spondylodiscitis: A Retrospective Analysis of 201 Patients

Max Prost, Melanie Elisabeth Röckner, Malte Kohns Vasconcelos, Joachim Windolf and Markus Rafael Konieczny

*Int J Spine Surg* 2023, 17 (4) 607-614

doi: <https://doi.org/10.14444/8482>

<http://ijssurgery.com/content/17/4/607>

This information is current as of April 29, 2024.

---

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://ijssurgery.com/alerts>

# Outcome of Targeted vs Empiric Antibiotic Therapy in the Treatment of Spondylodiscitis: A Retrospective Analysis of 201 Patients

MAX PROST, MD<sup>1</sup>; MELANIE ELISABETH RÖCKNER, MD<sup>1</sup>; MALTE KOHNS VASCONCELOS, MD<sup>2</sup>;  
JOACHIM WINDOLF, MD<sup>1</sup>; AND MARKUS RAFAEL KONIECZNY, MD<sup>1,3</sup>

<sup>1</sup>Department of Orthopedic and Trauma Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany; <sup>2</sup>Institute for Medical Microbiology and Hospital Hygiene, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany; <sup>3</sup>Department of Spine Surgery, Volmarstein Orthopedic Clinic, Volmarstein, Germany

## ABSTRACT

**Background:** Antibiotic treatment of spondylodiscitis is influenced by antibiotic stewardship; specifically, empirical antibiotic therapy is avoided in favor of—delayed—targeted antibiotic therapy after microbiological diagnosis. Only patients with neurological deficits or clinical signs of sepsis should be treated by empirical antibiotic therapy. However, the level of evidence for this treatment concept is weak.

**Purpose:** The aim of this study was to investigate whether patients who were treated with a nontargeted antibiotic therapy show a worse outcome than patients who were exclusively treated with targeted antibiotic therapy.

**Study Design/Setting:** A retrospective single-center data analysis.

**Patient Sample:** We included 201 patients with spondylodiscitis who were treated at the authors' institution between 2013 and 2020.

**Outcome Measures:** Mortality rate, time in hospital, development of laboratory parameters, and development of pain (visual analog scale).

**Methods:** We performed a retrospective data analysis of patients who were treated for spondylodiscitis from January 2013 to March 2020. Clinical and demographic data as well as outcome and complications were recorded and analyzed. We investigated whether patients who were treated by a nontargeted antibiotic therapy had a worse outcome than patients who were exclusively treated by targeted antibiotic therapy and which other clinical factors had an impact on clinical outcome.

**Results:** A total of 201 patients were included, 37 of whom developed sepsis during their hospital stay, and 14 of these 37 patients died. The 14 patients who died represented (10.0%) of the subgroup who received an empirical antibiotic treatment before the targeted antibiotic therapy ( $n = 141$ ). There were 0 deaths in the subgroup who did not receive an empirical antibiotic treatment ( $P < 0.05$ ). The time to diagnosis since admission to the hospital was 10.5 (2.2) days in patients with sepsis; in patients without sepsis, it was 5.2 (0.9) days ( $P < 0.05$ ).

**Conclusions:** Based on the results of this investigation, the authors recommend delaying antibiotic therapy until targeted antibiotic therapy is possible. Furthermore, early diagnosis of spondylodiscitis and prevention and early detection of sepsis are essential to reduce the mortality rate of patients with spondylodiscitis.

**Level of Evidence:** 3.

Other and Special Categories

Keywords: spine, vertebral osteomyelitis, spinal discitis, treatment strategies, antibiotic stewardship

## INTRODUCTION

Spondylodiscitis is an infectious disease of the spine, which usually shows unspecific clinical symptoms.<sup>1–3</sup> The incidence of spondylodiscitis varies between 1:100,000 and 1:250,000 and represents around 3% to 5% of all cases of osteomyelitis.<sup>3,4</sup>

Due to the unspecific clinical symptoms of patients with spondylodiscitis, there is a delay of 2 to 6 months between the beginning of the first symptoms and the diagnosis.<sup>1–3,5,6</sup> This delay may be the main reason why spondylodiscitis is a severe and potentially

life-threatening disease. The mortality rate of spondylodiscitis has been reported to be between 2% and 20%.<sup>7</sup>

The key component of a successful treatment for spondylodiscitis is to treat the infection with adequate antibiotic treatment.<sup>8,9</sup> Additional surgical treatment might be necessary as an internal fixation if instability of a spinal segment is detected<sup>7,10,11</sup> or if an operative debridement and decompression of the spinal canal is necessary.<sup>12,13</sup>

The most commonly detected microbiological pathogen in spondylodiscitis is *Staphylococcus aureus*<sup>6,14–16</sup>

followed by Gram-negative pathogens in 4% to 30% of the cases and streptococci or enterococci in 5% to 30% of the cases.<sup>17</sup> Polymicrobial infections are unusual, occurring in about 2.5% of the total number of cases.<sup>7</sup>

Pathogen detection is mostly performed by blood culture, percutaneous biopsy, or intraoperative tissue sampling.<sup>2,4,15,18</sup> However, identification of the pathogen is only successful in 49% to 83% of cases.<sup>5,10,15,16,18,19</sup> One of the main reasons for the failure of pathogen identification is a prior empiric antibiotic therapy.<sup>4</sup>

Antibiotic stewardship programs are becoming more widely implemented and therefore strongly influence the treatment of spondylodiscitis.<sup>16,20,21</sup> To avoid ineffective or unnecessarily toxic or expensive treatments, empirical antibiotic therapy is avoided in favor of delayed targeted antibiotic therapy after microbiological diagnosis. For this reason, it is particularly important that the antimicrobial treatment is not commenced until the exact pathogen is identified. An exception from this procedure is mandatory in patients with severe sepsis, which should be treated by an empirical antibiotic regimen.<sup>9</sup>

The level of evidence for this treatment concept is still weak.<sup>3,9,22</sup> Therefore, we conducted an investigation on this topic. The primary objective of this study was to analyze whether there are significant differences in the outcome of patients with spondylodiscitis who received a target antibiotic therapy compared with the outcome of those who received empirical antibiotic therapy.

## MATERIALS AND METHODS

This study was designed as a single-center retrospective cohort study and was performed in cooperation with the local Institute for Medical Microbiology and Hospital Hygiene.

Patients who needed to be treated for spondylodiscitis as an inpatient in our institution between January 2013 and March 2020 were identified in the clinical documentation system by diagnostic code. Inclusion and exclusion criteria are listed in Table 1.

Clinical and demographic data as well as outcome and complications were recorded and analyzed. As potential outcome parameters, we collected data on the duration of the hospital stay, need for surgery, development of laboratory parameters of the infection, development of pain, and level of mobility for each patient as well as the mortality rate. Furthermore, we noted whether patients developed sepsis during the hospital stay. Sepsis was defined according to the 2016 updated guidelines from Singer et al with an increase in the

**Table 1.** Inclusion and exclusion criteria.

Inclusion Criteria	Exclusion Criteria
Diagnosis of spondylodiscitis with:	Diagnosis of spondylodiscitis with:
<ul style="list-style-type: none"> <li>● Pain at rest</li> <li>● Radiological signs for spondylodiscitis</li> <li>● Laboratory signs of infection</li> </ul>	<ul style="list-style-type: none"> <li>● Signs of sepsis or severe neurological deficit at the time of admission to our hospital</li> </ul>
Complete set of data, including:	Incomplete set of data
<ul style="list-style-type: none"> <li>● Operative treatment</li> <li>● Antibiotic treatment</li> <li>● Microbiological results</li> </ul>	

Sequential Sepsis-related Organ Failure Assessment score of 2 points or more. The score is based on 6 different scores, 1 each for the following systems: respiratory (ratio between PaO<sub>2</sub>/FiO<sub>2</sub>), cardiovascular (mean arterial pressure or administration of vasopressors required), hepatic (bilirubin level), coagulation (number of plates), renal (creatinine or urine output), and neurological (Glasgow Coma Scale) systems.<sup>23</sup> Surgery was normally performed in patients with neurological deficit, sepsis, epidural abscess, instability, or failure of the conservative treatment.

We documented the performed antibiotic treatment protocols and the identified pathogens for each patient. If antibiotic therapy was commenced before a pathogen was identified, it was classified as empirical antibiotic treatment. All patients received at least 6 weeks of antibiotic treatment with a minimum of 2 weeks of intravenous administration of antibiotics. We investigated whether patients who received nontargeted (empirical) antibiotic therapy had a worse outcome compared with patients who received targeted antibiotic therapy and which other clinical factors had an impact on clinical outcome.

Statistical analysis was performed by SPSS 25 (IBM, Armonk, USA). Descriptive data are given as mean and SEM. We tested all continuous variables for normal distribution by Kolmogorov-Smirnov tests. None of the variables showed normal distribution. Thus, we performed  $\chi^2$  tests and Mann-Whitney *U* tests.

This study was approved by the local ethics committee of a university hospital (Register number 2020–914) and was conducted according to the revised Declaration of Helsinki.

## RESULTS

We identified 253 patients who were treated for spondylodiscitis as inpatients in our institution between January 2013 and March 2020. After the application of

the inclusion and exclusion criteria, we enrolled 201 patients to our investigation. Thirty-one patients were excluded due to an incomplete set of data, 11 patients were excluded due to severe neurological deficits at the time of admission to the hospital, and 10 patients were excluded due to severe clinical signs of sepsis at the time of admission to the hospital.

Eighty-seven patients were women (43.3%) and 114 were men (56.7%). The mean age of the patient was 65.5 (0.99) years. Seventy-four (36.8%) patients were classified as multimorbid.

The mean duration of the hospital stay was 33.63 (1.78) days. The time to diagnosis since admission to the hospital was 6.3 (0.8) days for all patients. In patients with sepsis, it was 10.5 (2.2) days, and in patients without sepsis, it was 5.2 (0.9) days ( $P < 0.05$ , effect size 0.63).

Overall, 123 (61.2%) patients received conservative treatment, and 78 (38.8%) patients needed an operative treatment for spondylodiscitis. Fourteen (7%) patients died, and 187 (93%) were discharged from the hospital. In 66 (32.8%) of the 201 patients, complications such as sepsis, intraspinal abscess, or unstable fracture occurred. Of the 14 patients who died, 13 (92.9%) patients were multimorbid. Approximately 40% (74 of 184) of the successfully treated patients underwent surgery during the hospital stay, whereas only 28.6% (4 of 14) of the patients who died underwent surgery.

In 140 patients (69.7%), the type of pathogen could be identified. The identified pathogens are shown in Table 2. In 22 (10.9%) patients, more than one pathogen could be identified. *S aureus* was most commonly detected. From the 74 cases of *S aureus*, 13.5% were methicillin-resistant *S aureus* (MRSA). Overall, MRSA was detected in 5% of our study population. Pathogens summed up under “others” were *Fusobacterium nucleatum*, *Klebsiella pneumoniae*, *Parvimonas micra*, *Proteus vulgaris*, *Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, *Serratia marcescens*, and *Salmonella enteritidis*.

**Table 2.** Type of detected pathogen.

Type of Pathogen	n	%
<i>Staphylococcus aureus</i>	74	36.8
<i>Staphylococcus epidermidis</i>	25	12.4
<i>Streptococcus spp.</i> (excluding <i>S pneumoniae</i> )	12	6.0
<i>Escherichia coli</i>	11	5.5
<i>Enterococcus</i>	10	5.0
<i>Mycobacteriaceae</i>	5	2.5
Other <sup>a</sup>	23	11.4

<sup>a</sup>Includes *Klebsiella pneumoniae*, *Parvimonas micra*, *Proteus vulgaris*, *Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, *Serratia marcescens*, and *Salmonella enteritidis*.

*S aureus* was also the most common pathogen in all the patients who died. The rate of patients in whom *S aureus* was detected was higher in the patients who died than in the overall collective (57.1% vs 36.8%). *Escherichia coli* is another pathogen that was more frequently detected in the patients who died. *Escherichia coli* was detected in 5.5% in the overall collective of patients and in 21.4% of the patients who died. All patients in whom a pathogen was detected and who died were from the subgroup of patients who received empirical antibiotic treatment prior to targeted antibiotic treatment.

The methods of pathogen identification are shown in Table 3. The method of pathogen identification had no effect on time-to-treatment with targeted antibiotics or on the patients' outcome.

In every patient in whom a pathogen could be detected, the targeted antibiotic treatment started within a mean of 0.95 (0.2) days. Time-to-treatment with targeted antibiotic treatment after identification of the pathogen in blood cultures was a mean of 0.9 (0.3) days; after detection in an intraoperative specimen, 1.1 (0.3) days; after detection in probes from a percutaneous puncture, 1.0 (0.1) days; and after simultaneous detection in multiple probes, 0.9 (0.2) days. The method of pathogen identification in the subgroups of patients who developed sepsis or died during the hospital stay showed no significant impact on the time to treatment of targeted antibiotic therapy (Table 3).

Every patient in whom a pathogen could be identified received targeted antibiotic therapy. Mean time-to-treatment with a targeted antibiotic was 13.5 (4.0) days in patients who survived and 1.8 (1.7) days in patients who died ( $P < 0.05$ , high statistical power of 0.95). An additional infection other than spondylodiscitis was suspected in 80 (39.8%) of the patients. Endocarditis was diagnosed in 16 of these 80 patients. An iatrogenic origin of the spondylodiscitis was found in 27 (13.4%) patients.

Every patient who died during the hospital stay had a nonvertebral infection site in addition to the spondylodiscitis. Six of the 14 patients who died had pneumonia in addition to the spondylodiscitis, and 3 of the 14 patients who died had endocarditis.

Fourteen of 141 patients (10.0%) who received empirical antibiotic treatment with or without a following targeted therapy died. One of these 14 patients received empiric antibiotic therapy because no pathogen could be isolated. Thirteen of the 14 patients who died received targeted antibiotic therapy after the empiric treatment. Out of all the patients who did not receive empirical antibiotic treatment, 0 died ( $P < 0.05$ ). The

**Table 3.** Type of specimen for identification of the pathogen.

Specimen	n	%
No identification	63	31.3
Blood	65	32.3
Intraoperative specimen	40	19.9
Percutaneous puncture	19	9.5
More than one	11	5.5
No information	3	1.5
Total	201	100.0

outcome of the patients and the development of sepsis depending on the antibiotic treatment regime is shown in the Figure.

Thirty-seven of 201 patients developed sepsis during their hospital stay, and 14 of these 37 patients died. None of the patients without sepsis (0 of 164) died ( $P < 0.001$ , effect size 0.61 [high]). The mean duration between hospital admission and diagnosis of spondylodiscitis was 10.5 (2.17) days in cases of sepsis and 5.2 (0.85) days in cases without sepsis ( $P < 0.025$ , effect size 0.77 [high]). The mean duration for identification of the pathogen in patients with sepsis was 1.8 (1.7) days.


In the patients who developed sepsis during the hospital stay, the rate of patients in whom *S aureus* (56.7% vs 36.8%) or *E coli* was detected (8.1% vs 5.5%) was higher than in the overall collective. In both subgroups (empirical antibiotic treatment prior to targeted antibiotic

treatment and targeted antibiotic treatment only), there was a predominance of *S aureus* in the patients who developed sepsis during the hospital stay. *E coli* was only predominant in the subgroup of patients who received empirical antibiotic treatment prior to targeted antibiotic treatment. The differences between these subgroups were not significant. The rate of patients with sepsis in whom no pathogen could be detected was less than in the overall group of patients (21.6% vs 30.3%).

## DISCUSSION

In this investigation, we analyzed the data of 201 patients to examine whether there were significant differences in the outcome of patients who received a targeted vs an empirical antibiotic treatment due to spondylodiscitis. The demographic data of our group of patients with a mean age of 65.5 years and a male predominance are comparable to data reported in other investigations.<sup>4,7,24,25</sup> This suggests that our study population was representative.

Sobottke et al reported a successful pathogen detection in 49% up to 83% of the cases.<sup>4</sup> In our group of patients, we were able to detect the pathogen in 69.7% of the cases. The most successful method of pathogen detection in our group of patients was through blood



**Figure.** Outcome of the patients according to the subgroup analysis.



cultures, followed by operative biopsies and computer tomography-guided needle biopsies. None of these latter techniques of pathogen detection were more effective than the others in our group of patients. Thus, we recommend combining the different techniques of pathogen detection. This recommendation is comparable to that of other studies.<sup>2-8,13,16,18,21</sup>

The spectrum of pathogens in our group of patients is different compared with the reported data from other study groups. As in former reports, *S aureus* was the most commonly detected pathogen in our group of patients with spondylodiscitis.<sup>4,6,7,15,16,26</sup> However, we also found a significantly lower number of Gram-negative pathogens and a significantly higher number of patients with multiple pathogens.

When looking at the subgroups of patients who developed sepsis or died during the hospital stay, the rate of patients in whom *S aureus* or *E coli* was detected was higher than in patients who did not die or develop sepsis. This finding suggests that these 2 pathogens are more aggressive than others. Patients in whom these pathogens are detected should, based on these results, be observed even more carefully for potential signs of sepsis. In our investigation, we did not explicitly analyze the virulence of the detected pathogen, which is known to have an important influence on the patient's outcome and the risk of developing sepsis.

Spondylodiscitis is often transferred hematogenously—because of bacteremia—from either the skin, the respiratory tract, the genitourinary tract, the gastrointestinal tract, or the oral cavity.<sup>16,27-29</sup> In our group of patients, we found another nonvertebral site of infection in 40% of the patients. An iatrogenic origin for spondylodiscitis was found in 13.4% of the cases. Every patient who died had a nonvertebral infection site in addition to spondylodiscitis. This is potentially caused by the fact that every patient who died developed sepsis. Developing additional infection sites is more likely in patients with sepsis, presumably because of bacteremia, than in patients without sepsis. However, we were not able to discern whether the patient's spondylodiscitis was the primary or the secondary infection site.<sup>23</sup>

Our data showed that the most severe complication in patients with spondylodiscitis was sepsis. None of the patients without sepsis died. In our group of patients, sepsis occurred in 18% of the cases. In patients who developed clinical signs of sepsis, the diagnosis of spondylodiscitis had been established significantly later than in those patients without sepsis. This fact shows that an early diagnosis of spondylodiscitis is essential for a successful treatment. Spondylodiscitis should always be considered

when a patient presents with general signs of an infection of unknown origin. Due to generalized pain and lack of movement in these patients, back pain as a key symptom of spondylodiscitis could stay undetected under the veil of the multitude of symptoms.

Our data showed that only patients with sepsis died. This may indicate that it is safe to postpone antibiotic treatment for patients without sepsis until successful pathogen detection.

If there are no signs of sepsis but clinical symptoms of infection are still present, we recommend taking blood cultures every second day for a period of 10 to 14 days. If no pathogen is detected in this period, we recommend beginning an empirical antibiotic treatment. Patients with sepsis need an immediate start of an empirical antibiotic treatment, if possible directly after the first blood culture or biopsy has been taken. Based on recent literature, we recommend at least 6 weeks of antibiotic treatment.<sup>16,25</sup>

Navarro-Navarro et al showed that biopsies had significantly more often positive results if no antibiotic treatment was given before the biopsy, which also suggests clinical benefits for the patient if no empiric antibiotic treatment is given before the pathogen could be identified.<sup>18</sup>

The mean duration between hospital admission and the beginning of targeted antibiotic treatment was significantly longer (13.5 vs 1.8 days) in patients who did not die than in patients who died. However, the earlier onset of targeted antibiotic therapy in patients who died might be due to a positive blood culture of critical patients, who have bacteremia, in contrast to noncritical patients, who contained the infection locally.<sup>30</sup>

Patients who died during inpatient treatment of spondylodiscitis received empirical antibiotic therapy significantly more often than patients who did not die. No patient who did not receive empirical antibiotic therapy died. A bias of this investigation is that we did not perform a separate analysis of patients who exclusively had an empiric antibiotic treatment and patients who had empiric antibiotic treatment prior to targeted antibiotic therapy. This subanalysis could not be performed due to issues with multiple testing (determined during the prior power analysis for the study design) and because of the different sizes of the groups. However, due to the high statistical power of the result and because the timing of the beginning of the targeted antibiotic therapy did not show any significant influence on patient outcome, our data seem to indicate that empirical antibiotic therapy should be avoided if possible (no clinical signs of sepsis, no neurological deficits).

Several investigations report a poorer outcome for patients if a nonsensitive antibiotic treatment (ie, an

antibiotic treatment to which the pathogen is immune) is administered.<sup>4,8,9,16,20,21</sup> The group of patients who received exclusively an empirical antibiotic treatment without a change of the antibiotic regimen after identification of a pathogen consisted—naturally—of patients in whom no pathogen could be identified. Since the type of empirical antibiotic treatment is selected with the aim to be effective on the most likely pathogens, by “luck” or by a careful selection of the antibiotic treatment, effective empirical antibiotic treatment will in most cases prevent identification of the pathogen because a high percentage of the pathogens are effectively eliminated. Those patients in whom a pathogen could be detected after administration of an empirical antibiotic treatment have, in most cases, received a noneffective—or less effective—for “their” pathogen) empirical antibiotic treatment, which led to persistent bacteremia and made identification of the pathogen possible. These patients, in our investigation, showed an inferior outcome than patients who exclusively received targeted antibiotic treatment. Considering that there are many possible confounding factors for the other analysis, we decided, prior to the investigation, to analyze the 2 latter groups.

Comparable to the literature, our data showed that dying from spondylodiscitis was significantly associated with multimorbidity.<sup>16,25</sup> Patients who died underwent surgery less often (28.6% vs 39.6%) during the hospital stay. This may result from the fact that these patients had medical conditions that did not allow for surgical procedures under general anesthesia.

A limitation of our investigation is that we performed retrospective data analysis and that there was no official study protocol for the treatment of the patients. However, due to a standard operating procedure in our department according to the treatment of spondylodiscitis, the treatment of the patients was comparable without an official study protocol.

## CONCLUSION

Based on the results of our investigation, we recommend delaying antibiotic therapy until targeted antibiotic therapy is possible. Furthermore, our data suggest that an early diagnosis of spondylodiscitis, along with prevention and early detection of sepsis, is essential to reduce the mortality rate of patients with spondylodiscitis.

## ACKNOWLEDGMENTS

From 2009 to July 2018, patients were treated in the Department of Orthopedic Surgery by Dr R. Kraupse.

Patients included between August 2018 and March 2020 were treated in the Department of Orthopedic and Trauma Surgery by Dr J. Windolf.

## REFERENCES

1. Müller EJ, Russe OJ, Muhr G. Osteomyelitis of the spine. *Orthopade*. 2004;33(3):305–315. doi:10.1007/s00132-003-0603-2
2. Nolla JM, Ariza J, Gómez-Vaquero C, et al. Spontaneous pyogenic vertebral osteomyelitis in nondrug users. *Semin Arthritis Rheum*. 2002;31(4):271–278. doi:10.1053/sarh.2002.29492
3. Zarghooni K, Röllinghoff M, Sobottke R, Eysel P. Treatment of spondylodiscitis. *Int Orthop*. 2012;36(2):405–411. doi:10.1007/s00264-011-1425-1
4. Sobottke R, Seifert H, Fätkenheuer G, Schmidt M, Gossmann A, Eysel P. Current diagnosis and treatment of spondylodiscitis. *Dtsch Arztebl Int*. 2008;105(10):181–187. doi:10.3238/arztebl.2008.0181
5. Butler JS, Shelly MJ, Timlin M, Powderly WG, O’Byrne JM. Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center. *Spine (Phila Pa 1976)*. 2006;31(23):2695–2700. doi:10.1097/01.brs.0000244662.78725.37
6. Berbari EF, Kanj SS, Kowalski TJ, et al. Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. *Clin Infect Dis*. 2015;61(6):859–863. doi:10.1093/cid/civ633
7. Skaf GS, Domloj NT, Fehlings MG, et al. Pyogenic spondylodiscitis: an overview. *J Infect Public Health*. 2010;3(1):5–16. doi:10.1016/j.jiph.2010.01.001
8. Gasbarrini AL, Bertoldi E, Mazzetti M, et al. Clinical features, diagnostic and therapeutic approaches to haematogenous vertebral osteomyelitis. *Eur Rev Med Pharmacol Sci*. 2005;9(1):53–66.
9. Grados F, Lescure FX, Senneville E, Flipo RM, Schmit JL, Fardellone P. Suggestions for managing pyogenic (non-tuberculous) discitis in adults. *Joint Bone Spine*. 2007;74(2):133–139. doi:10.1016/j.jbspin.2006.11.002
10. Frangen TM, Källicke T, Gottwald M, et al. Die operative therapie der spondylodiscitis. *Unfallchirurg*. 2006;109(9):743–753. doi:10.1007/s00113-006-1084-7
11. Oden AT, Kaiser MG. Single-stage debridement and instrumentation for pyogenic spinal infections. *Neurosurg Focus*. 2004;17(6):E5:1–5. doi:10.3171/foc.2004.17.6.5
12. Eismont FJ, Bohlman HH, Soni PL, Goldberg VM, Freehafer AA. Pyogenic and fungal vertebral osteomyelitis with paralysis. *J Bone Joint Surg Am*. 1983;65(1):19–29.
13. Osenbach RK, Hitchon PW, Menezes AH. Diagnosis and management of pyogenic vertebral osteomyelitis in adults. *Surg Neurol*. 1990;33(4):266–275. doi:10.1016/0090-3019(90)90047-s
14. Mann S, Schütze M, Sola S, Piek J. Nonspecific pyogenic spondylodiscitis: clinical manifestations, surgical treatment, and outcome in 24 patients. *Neurosurg Focus*. 2004;17(6):E3. doi:10.3171/foc.2004.17.6.3
15. Başak AT, Çakıcı N, Özbek MA, et al. A combined diagnosis and treatment algorithm for spine infection management: a single-center experience. *Cureus*. 2022;14(8):e28251.
16. Tsantes AG, Papadopoulos DV, Vriani G, et al. Spinal infections: an update. *Microorganisms*. 2020;8(4):476. doi:10.3390/microorganisms8040476
17. Cottle L, Riordan T. Infectious spondylodiscitis. *J Infect*. 2008;56(6):401–412. doi:10.1016/j.jinf.2008.02.005

18. Navarro-Navarro R, Suárez-Cabañas AH, Fernández-Varela T, Lorenzo-Rivero JA, Montesdeoca-Ara A. Analysis of results of open and percutaneous disc biopsy in the diagnosis of spondylodiscitis. Análisis de los resultados de la biopsia discal abierta y percutánea en el diagnóstico de la espondilodiscitis. *Rev Esp Cir Ortop Traumatol*. 2022;66(3):189–199.
19. Schinkel C, Gottwald M, Andress H-J. Surgical treatment of spondylodiscitis. *Surg Infect (Larchmt)*. 2003;4(4):387–391. doi:10.1089/109629603322761445
20. Campbell KA, Stein S, Looze C, Bosco JA. Antibiotic stewardship in orthopaedic surgery: principles and practice. *J Am Acad Orthop Surg*. 2014;22(12):772–781. doi:10.5435/JAAOS-22-12-772
21. Gregori F, Grasso G, Iaiani G, Marotta N, Torregrossa F, Landi A. Treatment algorithm for spontaneous spinal infections: a review of the literature. *J Craniovertebr Junction Spine*. 2019;10(1):3–9. doi:10.4103/jcvjs.JCVJS\_115\_18
22. Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. *J Antimicrob Chemother*. 2010;65 Suppl 3:iii11–iii24. doi:10.1093/jac/dkq303
23. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA*. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
24. Kourbeti IS, Tsiodras S, Boumpas DT. Spinal infections: evolving concepts. *Curr Opin Rheumatol*. 2008;20(4):471–479. doi:10.1097/BOR.0b013e3282ff5e66
25. Rutges J, Kempen DH, van Dijk M, Oner FC. Outcome of conservative and surgical treatment of pyogenic spondylodiscitis: a systematic literature review. *Eur Spine J*. 2016;25(4):983–999. doi:10.1007/s00586-015-4318-y
26. Hohenberger C, Schmidt NO, Doenitz C, Ullrich OW, Schebesch KM. Infectious spondylodiscitis of the lumbar spine: conservative antibiotic therapy vs. antibiotic therapy with surgery, and the time of surgery. *Neurol India*. 2022;70(1):155–159. doi:10.4103/0028-3886.338724
27. Govender S. Spinal infections. *J Bone Joint Surg Br*. 2005;87(11):1454–1458. doi:10.1302/0301-620X.87B11.16294
28. Kiefer SP, Hlavin ML. Harvey cushing and claude beck: a surgical legacy. *Neurosurgery*. 1996;38(6):1223–1230. doi:10.1097/00006123-199606000-00035
29. Reihnsaus E, Waldbaur H, Seeling W. Spinal epidural abscess: a meta-analysis of 915 patients. *Neurosurg Rev*. 2000;23(4):175–204. doi:10.1007/pl00011954
30. Towns ML, Jarvis WR, Hsueh P-R. Guidelines on blood cultures. *J Microbiol Immunol Infect*. 2010;43(4):347–349. doi:10.1016/S1684-1182(10)60054-0

**Funding:** The authors received no financial support for the research, authorship, and/or publication of this article.

## Declaration of Conflicting Interests:

M.R.K. reports personal fees from Globus Medical outside the submitted work.

## Authors Contributions:

M.P.: conception and design, administrative support, collection and assembly of data, provision of study materials or patients, data analysis and interpretation, manuscript writing, and final approval of manuscript. M.E.R.: administrative support, collection and assembly of data, provision of study materials or patients, data analysis and interpretation, manuscript writing, and final approval of manuscript. M.K.V.: administrative support, collection and assembly of data, manuscript writing, and final approval of manuscript. J.W.: administrative support, provision of study materials or patients, manuscript writing, and final approval of manuscript. M.R.K.: administrative support, collection and assembly of data, provision of study materials or patients, data analysis and interpretation, manuscript writing, and final approval of manuscript.

## Ethical Statement:

This study was approved by the local ethics committee (Register number 2020-914) and was conducted according to the revised Declaration of Helsinki. Consent to participate was not applicable because of the retrospective design of the investigation.

## Data Availability Statement:

The datasets generated during and/or analyzed during the current study are not publicly available due data protection but are available from the corresponding author on reasonable request.

## Corresponding Author:

Max Prost, Department of Orthopedic and Trauma Surgery, University Hospital Duesseldorf, Moorenstraße 5, 40225 Düsseldorf, Germany; Max.prost@med.uni-duesseldorf.de

This manuscript is generously published free of charge by ISASS, the International Society for the Advancement of Spine Surgery. Copyright © 2023 ISASS. To see more or order reprints or permissions, see <http://ijssurgery.com>.



**COMMENTARY:**

This article, which sought to “investigate whether patients who were treated by a nontargeted antibiotic therapy show a worse outcome than patients who have exclusively been treated by a targeted antibiotic therapy,” is a retrospective review over an extended period (2013-2020), which limits the applicability of the findings. Although the majority of spine literature is retrospective in nature, a great amount of knowledge can be gained from this literature. However, readers must understand the limitations of a retrospective study, particularly as in a long-term study such as this one, because numerous variables that can affect the outcome may change. For example, did the surgeons, patient population, antibiotic usage, laboratory abilities, surgical and medical techniques, etc, change? Furthermore, when was the diagnosis of spondylodiscitis determined and how did that influence care or timing of treatment? Often, these patients present clinically unstable before the discitis source is identified. (In this study, septic patients were excluded, but were they pre-septic?)

The authors noted that 10% (14/141) of the empirical antibiotic-treated patients died and that this group was compared to the patients who had targeted therapy. Although 201 patients were included in the study, only 141 of them were selected to get empiric treatment. Why? And was this a selection bias? One would assume that this group would be the sicker population since the physicians questioned an infectious etiology in their presentation and treated them. Thus, we have introduced another significant selection bias. Another issue is that in 31% of patients, a pathogen was not identified, which is high when comparing effective treatment strategies. Therefore, it must be assumed that some of these patients may not have had an infectious etiology. Thus, antibiotics would not affect their overall survival and conclusions that early targeted antibiotics would have been beneficial are limited. Furthermore, this study is directed at spine physicians, but every mortality was in a patient who had, in addition to the spine, another nonvertebral site of infection. This population is clearly different than those with primary spondylodiscitis, because in these patients the spine was most likely the secondary site of infection, hence the higher mortality rate. If the primary site had been addressed earlier, would the spine not have been influential in their outcome?

This is an interesting study, and the authors are commended for their research and analysis on a difficult topic. They conclude by recommending that physicians “delay antibiotic therapy and targeted antibiotic therapy if possible.” I would suggest that as clinicians, we appreciate these comments. In clinical scenarios in which patients are critically ill or have a high known incident of a certain bacterial specimen (eg, staph aureus in intravenous users), then empiric treatment appears appropriate. The authors’ message of early and aggressive diagnosis of an infection is important, and in clinically stable patients, obtaining a diagnosis before antibiotics may be appropriate. Clearly, more research is needed in this area, and this study adds to our fund of knowledge.

James Harrop, MD  
IJSS Deputy Editor